Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

被引：485

作者：

Hallberg, Bengt ^{[1
]}

Palmer, Ruth H. ^{[1
]}

机构：

[1] Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden

来源：

NATURE REVIEWS CANCER | 2013年 / 13卷 / 10期

基金：

瑞典研究理事会;

关键词：

ANAPLASTIC LYMPHOMA KINASE; LARGE-CELL LYMPHOMA; INFLAMMATORY MYOFIBROBLASTIC TUMOR; NPM-ALK; LUNG-CANCER; MOLECULAR CHARACTERIZATION; DOWN-REGULATION; TRUNCATED FORM; GROWTH-FACTOR; FUSION GENE;

D O I：

10.1038/nrc3580

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The burgeoning field of anaplastic lymphoma kinase (ALK) in cancer encompasses many cancer types, from very rare cancers to the more prevalent non-small-cell lung cancer (NSCLC). The common activation of ALK has led to the use of the ALK tyrosine kinase inhibitor (TKI) crizotinib in a range of patient populations and to the rapid development of second-generation drugs targeting ALK. In this Review, we discuss our current understanding of ALK function in human cancer and the implications for tumour treatment.

引用

页码：685 / 700

页数：16

共 50 条

[21] Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
Lovly, Christine M.
Heuckmann, Johannes M.
de Stanchina, Elisa
Chen, Heidi
Thomas, Roman K.
Liang, Chris
Pao, William
CANCER RESEARCH, 2011, 71 (14) : 4920 - 4931
[22] Alk and Ltk ligands are essential for iridophore development in zebrafish mediated by the receptor tyrosine kinase Ltk
Mo, Elizabeth S.
Cheng, Qianni
Reshetnyak, Andrey V.
Schlessinger, Joseph
Nicoli, Stefania
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (45) : 12027 - 12032
[23] Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer
Saintigny, Pierre
William, William N., Jr.
Foy, Jean-Philippe
Papadimitrakopoulou, Vassiliki
Lang, Wenhua
Zhang, Li
Fan, You Hong
Feng, Lei
Kim, Edward S.
El-Naggar, Adel K.
Lee, J. Jack
Mao, Li
Hong, Waun Ki
Lingen, Mark W.
Lippman, Scott M.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (03):
[24] The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)
Golding, Brandon
Luu, Anita
Jones, Robert
Viloria-Petit, Alicia M.
MOLECULAR CANCER, 2018, 17
[25] Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer
Yamaguchi, Norihiro
Lucena-Araujo, Antonio R.
Nakayama, Sohei
de Figueiredo-Pontes, Lorena L.
Gonzalez, David A.
Yasuda, Hiroyuki
Kobayashi, Susumu
Costa, Daniel B.
LUNG CANCER, 2014, 83 (01) : 37 - 43
[26] Role of the Non-Receptor Tyrosine Kinase Fes in Cancer
Condorelli, F.
Stec-Martyna, E.
Zaborowska, J.
Felli, L.
Gemmi, I.
Ponassi, M.
Rosano, C.
CURRENT MEDICINAL CHEMISTRY, 2011, 18 (19) : 2913 - 2920
[27] Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications
Quintanal-Villalonga, A.
Paz-Ares, Luis
Ferrer, Irene
Molina-Pinelo, S.
DISEASE MARKERS, 2016, 2016
[28] Non-receptor tyrosine kinase inhibitors in lung cancer
Hahn, Olwen
Salgia, Ravi
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2007, 7 (06) : 633 - 642
[29] The cytoplasmic truncated receptor tyrosine kinase ALK-homodimer immortalizes and cooperates with ras in cellular transformation
Simonitsch, I
Polgar, D
Hajek, M
Duchek, P
Skrzypek, B
Fassl, S
Lamprecht, A
Schmidt, G
Krupitza, G
Cerni, C
FASEB JOURNAL, 2001, 15 (06) : 1416 - +
[30] Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases
Rodig, Scott J.
Shapiro, Geoffrey I.
CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2010, 11 (12) : 1477 - 1490

← 1 2 3 4 5 →